RAPT Stock Summary and Trading Ideas (Rapt Therapeutics | NASDAQ:RAPT)

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Rapt Therapeutics trades on the NASDAQ stock market under the symbol RAPT.

As of April 23, 2024, RAPT stock price climbed to $8.00 with 315,896 million shares trading.

RAPT has a beta of 1.91, meaning it tends to be more sensitive to market movements. RAPT has a correlation of 0.03 to the broad based SPY ETF.

RAPT has a market cap of $278.38 million. This is considered a Small Cap stock.

In the last 3 years, RAPT stock traded as high as $43.26 and as low as $6.86.

The top ETF exchange traded funds that RAPT belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.

RAPT has underperformed the market in the last year with a price return of -59.5% while the SPY ETF gained +24.3%. RAPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -67.4% and -3.8%, respectively, while the SPY returned +4.9% and -2.5%, respectively.

RAPT support price is $7.55 and resistance is $8.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPT stock will trade within this expected range on the day.